MCID: ASP030
MIFTS: 47

Aspirin Resistance

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Aspirin Resistance

MalaCards integrated aliases for Aspirin Resistance:

Name: Aspirin Resistance 58
Aspirin, Resistance to Cardioprotective Effect of 58
Aspirin, Resistance to Antithrombotic Effect of 58
Aspirin Cardioprotective Effect of 58
Aspirin Antithrombotic Effect of 58

Classifications:



External Ids:

OMIM 58 608223

Summaries for Aspirin Resistance

OMIM : 58 Aspirin (acetylsalicylic acid) is a classic nonsteroidal antiinflammatory agent that irreversibly inhibits type I cyclooxygenase (PTGS1, or COX1; 176805) in platelets, resulting in decreased production of thromboxane A2 (TXA2) and inhibition of platelet aggregation. Because of this feature, it is used therapeutically to prevent cardiothrombotic events. Individuals show a variable response to the drug, referred to as aspirin ineffectiveness or resistance, in which not all individuals or populations appear to receive the full prophylactic or therapeutic benefits (summary by Zhou et al., 2011). Halushka and Halushka (2002) discussed a possible basis for resistance to the cardioprotective effect of aspirin. (608223)

MalaCards based summary : Aspirin Resistance, also known as aspirin, resistance to cardioprotective effect of, is related to myocardial infarction and arteries, anomalies of. An important gene associated with Aspirin Resistance is PTGS1 (Prostaglandin-Endoperoxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Focal Adhesion. The drugs Aspirin and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Aspirin Resistance

Diseases related to Aspirin Resistance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 myocardial infarction 28.8 APOB ITGA2 ITGB3 PTGS1 PTGS2
2 arteries, anomalies of 10.4
3 coronary artery anomaly 10.4
4 heart disease 10.2
5 active peptic ulcer disease 10.1 PTGS1 PTGS2
6 morphine dependence 10.1 PTGS1 PTGS2
7 ischemia 10.1
8 hydrops, lactic acidosis, and sideroblastic anemia 10.1 PTGS1 PTGS2
9 antenatal bartter syndrome 10.1 PTGS1 PTGS2
10 clopidogrel resistance 10.1 ITGB3 PTGS2
11 gastric ulcer 10.1 PTGS1 PTGS2
12 diabetes mellitus 10.1
13 dyspepsia 10.1 PTGS1 PTGS2
14 stomach disease 10.0 PTGS1 PTGS2
15 angioedema 10.0 PTGS1 PTGS2
16 coronary heart disease 1 10.0
17 thrombosis 10.0
18 vascular disease 10.0
19 cerebrovascular disease 10.0
20 gastroesophageal reflux 10.0 PTGS1 PTGS2
21 urticaria 10.0 PTGS1 PTGS2
22 gas gangrene 9.9
23 fetal and neonatal alloimmune thrombocytopenia 9.9 ITGA2 ITGB3
24 proteasome-associated autoinflammatory syndrome 1 9.9 PTGS1 PTGS2
25 thrombocytopenia due to platelet alloimmunization 9.9 ITGA2 ITGB3
26 primary thrombocytopenia 9.9 ITGA2 ITGB3
27 autoimmune disease of blood 9.9 ITGA2 ITGB3
28 von willebrand disease, type 2 9.9 ITGA2 ITGB3
29 thrombasthenia 9.9 ITGA2 ITGB3
30 rheumatic disease 9.9 PTGS1 PTGS2
31 peripheral vascular disease 9.9
32 acute myocardial infarction 9.9
33 diabetic angiopathy 9.9
34 glanzmann thrombasthenia 9.8 ITGA2 ITGB3
35 bernard-soulier syndrome 9.7 ITGA2 ITGB3
36 familial adenomatous polyposis 9.7 PTGS1 PTGS2
37 atherosclerosis susceptibility 9.7
38 systemic lupus erythematosus 9.7
39 neutrophil actin dysfunction 9.7
40 body mass index quantitative trait locus 11 9.7
41 stroke, ischemic 9.7
42 horns in sheep 9.7
43 body mass index quantitative trait locus 8 9.7
44 body mass index quantitative trait locus 10 9.7
45 body mass index quantitative trait locus 7 9.7
46 body mass index quantitative trait locus 14 9.7
47 body mass index quantitative trait locus 18 9.7
48 body mass index quantitative trait locus 19 9.7
49 angina pectoris 9.7
50 congestive heart failure 9.7

Graphical network of the top 20 diseases related to Aspirin Resistance:



Diseases related to Aspirin Resistance

Symptoms & Phenotypes for Aspirin Resistance

Clinical features from OMIM:

608223

MGI Mouse Phenotypes related to Aspirin Resistance:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.8 APOB ITGB3 PTGS1 PTGS2 TBXA2R
2 homeostasis/metabolism MP:0005376 9.8 APOB ITGA2 ITGB3 PTGS1 PTGS2 TBXA2R
3 hematopoietic system MP:0005397 9.77 ITGA2 ITGB3 PTGS1 PTGS2 TBXA2R
4 immune system MP:0005387 9.65 APOB ITGB3 PTGS1 PTGS2 TBXA2R
5 muscle MP:0005369 9.46 APOB ITGB3 PTGS1 PTGS2
6 reproductive system MP:0005389 9.35 APOB ITGB3 PTGS1 PTGS2 TBXA2R
7 respiratory system MP:0005388 8.92 ITGB3 PTGS1 PTGS2 TBXA2R

Drugs & Therapeutics for Aspirin Resistance

Drugs for Aspirin Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
2
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
3
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Racepinephrine Approved Phase 4 329-65-7 838
6
Dipyridamole Approved Phase 4 58-32-2 3108
7
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
8
Tirofiban Approved Phase 4,Phase 2 144494-65-5 60947
9
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
10
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
11
Pravastatin Approved Phase 4 81093-37-0 54687
12
Atorvastatin Approved Phase 4 134523-00-5 60823
13
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
14
arachidonic acid Experimental Phase 4 506-32-1 444899
15 Antipyretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 lysine Phase 4
19 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Acetylsalicylic acid lysinate Phase 4
22 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Vasodilator Agents Phase 4
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
29 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
30 Purinergic P2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
31 Neuroprotective Agents Phase 4
32 Autonomic Agents Phase 4
33 Bronchodilator Agents Phase 4
34 Respiratory System Agents Phase 4
35 Phosphodiesterase 3 Inhibitors Phase 4
36 Phosphodiesterase Inhibitors Phase 4
37 Anti-Asthmatic Agents Phase 4
38 Protective Agents Phase 4,Phase 2
39 Epinephryl borate Phase 4
40 Aspirin, Dipyridamole Drug Combination Phase 4
41 Adjuvants, Immunologic Phase 4,Phase 2
42 Antiviral Agents Phase 4,Phase 2
43 polysaccharide-K Phase 4,Phase 2
44 Radiation-Protective Agents Phase 4,Phase 2
45 Immunologic Factors Phase 4,Phase 2
46 interferons Phase 4,Phase 2
47 Anti-Infective Agents Phase 4,Phase 2
48 calcium heparin Phase 4
49 Anti-Bacterial Agents Phase 4,Phase 2
50 Interferon Inducers Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Aspirin Resistance Reversibility in Diabetic Patients Unknown status NCT01935193 Phase 4 lysine acetylsalicylate
2 Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
3 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
4 Overcome Biochemical Aspirin Resistance Through Cilostazol Combination Completed NCT00446641 Phase 4 Cilostazol;placebo
5 Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting Completed NCT01159639 Phase 4 Clopidogrel
6 Platelet Hyperreactivity to Aspirin and Stroke Completed NCT00766896 Phase 4 Aspirin (platelet sensitive versus platelet hyperreactivity)
7 Aspirin Responsiveness in Women at Risk for Cardiac Events Completed NCT00818337 Phase 4 Aspirin
8 Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
9 Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance Completed NCT00398463 Phase 4 Tirofiban;Placebo
10 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
11 Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent Completed NCT02410083 Phase 4 Clopirin 1;Clopidogrel-Aspirin(co-administration) 1;Clopirin 2;Clopidogrel-Aspirin(co-administration) 2
12 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4 aspirin;clopidogrel
13 Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index Completed NCT01502943 Phase 4 Louxiangdan Tongxin granules;TCM granules placebo;Chixiangshen Tongxin granules;TCM granule placebo plus western basis treatment;Western basis treatment
14 The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia Recruiting NCT03735433 Phase 4 162mg aspirin dose
15 Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients Withdrawn NCT01198379 Phase 4 aspirin;Placebo
16 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
17 Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance Unknown status NCT00697021 Phase 3 Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;Aspirin 100mg and Plavix 75mg
18 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
19 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events Completed NCT01586975 Phase 2, Phase 3 Clopidogrel;Aspirin 81 mg;Aspirin >300 mg
20 The Effects of Omega-3 Fatty Acids on Aspirin Resistance Completed NCT00771914 Phase 1, Phase 2 Aspirin;Lovaza;Both Aspirin and Lovaza
21 Aspirin Resistance and Percutaneous Coronary Intervention (PCI) Completed NCT01103440 Phase 2 Intravenous Glycoprotein inhibitor + ASA, Clopidogrel;Antiplatelet Therapy (ASA, Clopidogrel)
22 Fish Oil and Aspirin With Type 2 Diabetes Completed NCT01181882 Phase 2
23 Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial. Completed NCT02280031 Phase 2 Acetylsalicylic Acid;Placebo
24 In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction Unknown status NCT01047722 Phase 1 Aspirin ingestion followed by doing a Bleeding Volume Test
25 Mechanism Based Resistance to Aspirin Completed NCT00948987 Phase 1 Aspirin
26 Aspirin Resistance in Systemic Lupus Erythematosus (SLE) Completed NCT00731302 Phase 1 aspirin and meloxicam
27 Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient Unknown status NCT01045785
28 Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population Unknown status NCT01408927
29 Platelet Reactivity and MES During CEA Unknown status NCT01547039
30 Relationship Between Level of Hemoglobin A1c and Platelet Function in Patients Undergoing Cardiac Surgery Unknown status NCT02711124
31 Aspirin Resistance in OSA Patients Completed NCT03930875
32 Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients Completed NCT00792272
33 Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Completed NCT01104441
34 Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients Completed NCT01364779
35 The Effect of Serum LDL Lowering on Aspirin Resistance Completed NCT00466154 Not Applicable Aspirin
36 Danish Aspirin Resistance Trial - Pilot Study Completed NCT00389129 Not Applicable acetylsalicylic acid
37 Aspirin Resistance in Coronary Artery Disease Completed NCT00753935 Early Phase 1 enteric-coated aspirin;Chewable aspirin
38 Laboratory Aspirin Resistance in Diabetics and Non-Diabetics Completed NCT00563875 Not Applicable acetylsalicylic acid
39 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study) Completed NCT00250380
40 Enteric Coating as a Factor in Aspirin Resistance Completed NCT00531362 Plain aspirin
41 Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients Completed NCT00649909
42 The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery Completed NCT01432652
43 Genotypic and Phenotypic Correlates of Resistance to Aspirin Completed NCT01361620 Not Applicable aspirin
44 Optimum Platelet Inhibition After Coronary Bypass Surgery Completed NCT00262275 Not Applicable Aspirin, Clopidogrel
45 Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery Completed NCT01174862
46 Aspirin Responsiveness in Women With Coronary Artery Disease Completed NCT01406990
47 Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine Completed NCT01152229
48 The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort) Completed NCT01796691
49 Resistance on Antithrombotic Drugs in Ischemic Heart Disease Completed NCT00742430
50 Validation of an Assay to Measure Cyclooxygenase-1 Activity Completed NCT00761891 Not Applicable

Search NIH Clinical Center for Aspirin Resistance

Genetic Tests for Aspirin Resistance

Anatomical Context for Aspirin Resistance

MalaCards organs/tissues related to Aspirin Resistance:

42
Heart, Testes, Kidney, Endothelial, Whole Blood, Neutrophil

Publications for Aspirin Resistance

Articles related to Aspirin Resistance:

(show top 50) (show all 405)
# Title Authors Year
1
Obesity and Laboratory Aspirin Resistance in High Risk Pregnant Women Treated with Low Dose Aspirin. ( 30786253 )
2019
2
Aspirin resistance mediated by oxidative stress-induced 8-Isoprostaglandin F2. ( 30989683 )
2019
3
Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. ( 30820515 )
2019
4
Prevalence of aspirin resistance by thromboelastography plus platelet mapping in children with CHD: a single-centre experience. ( 30501653 )
2019
5
Investigation into the causes of aspirin resistance in healthy dogs. ( 30302763 )
2019
6
The association between aspirin resistance and extent and severity of coronary atherosclerosis. ( 30859163 )
2018
7
Identification of aspirin resistance using a PDW-miR92a-score: Validation in an intermittent claudication cohort. ( 30586555 )
2018
8
Aspirin resistance in the early postoperative period: Pharmacokinetics may be part of the answer. ( 30538026 )
2018
9
Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients. ( 30025441 )
2018
10
Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. ( 30016728 )
2018
11
Associations Between PFA-Measured Aspirin Resistance, Platelet Count, Renal Function, and Angiotensin Receptor Blockers. ( 29996660 )
2018
12
The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study. ( 29888621 )
2018
13
Aspirin Resistance: Cardiovascular Risk Game Changer. ( 29757761 )
2018
14
Aspirin Resistance: Risk Factors and Prognostic Significance in Patients with Cerebral Small Vessel Disease. ( 29530996 )
2018
15
Effects of Ramadan fasting on aspirin resistance in type 2 diabetic patients. ( 29529091 )
2018
16
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. ( 29090588 )
2018
17
PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study. ( 29055181 )
2018
18
Association of GPIa and COX-2 gene polymorphism with aspirin resistance. ( 28948649 )
2018
19
Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients. ( 28068952 )
2017
20
Over-expression of cyclooxygenase-2 in increased reticulated platelets leads to aspirin resistance after elective off-pump coronary artery bypass surgery. ( 29149707 )
2017
21
Biochemical aspirin resistance is associated with increased stroke severity and infarct volumes in ischemic stroke patients. ( 29100372 )
2017
22
Platelet Carbonic Anhydrase II, a Forgotten Enzyme, May Be Responsible for Aspirin Resistance. ( 29090039 )
2017
23
Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance. ( 28969559 )
2017
24
Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality. ( 28912955 )
2017
25
My Approach to the patient with CAD and aspirin resistance. ( 28865598 )
2017
26
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( 28842303 )
2017
27
The incidence of aspirin resistance in heart transplantation recipients. ( 28747943 )
2017
28
Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A Bibliometric Analysis. ( 28667787 )
2017
29
rs5911 and rs3842788 Genetic Polymorphism, Blood Stasis Syndrome, and Plasma TXB2 and hs-CRP Levels Are Associated with Aspirin Resistance in Chinese Chronic Stable Angina Patients. ( 28465708 )
2017
30
Suspected aspirin resistance in individual healthy adult warmblood horses. ( 28390056 )
2017
31
Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. ( 28033561 )
2017
32
Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical study
. ( 28025961 )
2017
33
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease. ( 28100965 )
2016
34
Aspirin resistance in coronary heart disease: Current understandings and strategies. ( 28191510 )
2016
35
Aspirin Resistance in Different Doses by Bleeding Time and Urinary 11-dehydro-thromboxane B2. ( 29953191 )
2016
36
Establishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular disease. ( 27594876 )
2016
37
High prevalence of aspirin resistance in elderly patients with cardiovascular disease and metabolic syndrome. ( 27582771 )
2016
38
The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis. ( 27393925 )
2016
39
A study into the genetic basis of aspirin resistance in Pakistani patients with coronary artery disease. ( 27393450 )
2016
40
A brief review on the mechanisms of aspirin resistance. ( 27372038 )
2016
41
Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients. ( 27318652 )
2016
42
Aspirin resistance may be identified by miR-92a in plasma combined with platelet distribution width. ( 27208561 )
2016
43
Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis. ( 27153119 )
2016
44
Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance. ( 27105311 )
2016
45
Aspirin resistance is associated with increased stroke severity and infarct volume. ( 27060166 )
2016
46
The lack of aspirin resistance in patients with coronary artery disease. ( 26980433 )
2016
47
Investigating the role of aspirin resistance in obstetrics may optimise prevention of pre-eclampsia. ( 26969603 )
2016
48
Low dose aspirin and pregnancy: how important is aspirin resistance? ( 26929162 )
2016
49
Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( 26809135 )
2016
50
Does high serum uric acid level cause aspirin resistance? ( 26656902 )
2016

Variations for Aspirin Resistance

Expression for Aspirin Resistance

Search GEO for disease gene expression data for Aspirin Resistance.

Pathways for Aspirin Resistance

Pathways related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 APOB ITGA2 ITGB3 TBXA2R
2
Show member pathways
12.55 ITGA2 ITGB3 PTGS2
3
Show member pathways
12.06 ITGB3 PTGS1 PTGS2
4
Show member pathways
11.91 APOB PTGS1 PTGS2
5 11.59 ITGA2 ITGB3
6 11.56 ITGA2 PTGS2
7 11.53 ITGB3 PTGS2
8 11.51 ITGA2 ITGB3
9 11.42 ITGB3 PTGS2
10 11.35 ITGA2 ITGB3 PTGS1 TBXA2R
11 11.31 ITGA2 ITGB3
12 11.29 PTGS1 PTGS2
13 11.2 PTGS1 PTGS2 TBXA2R
14 11.13 ITGA2 ITGB3
15 10.99 PTGS1 PTGS2
16
Show member pathways
10.91 PTGS1 PTGS2
17 10.84 PTGS1 PTGS2
18 10.79 PTGS1 PTGS2
19 10.78 PTGS1 PTGS2 TBXA2R
20 10.65 PTGS1 PTGS2
21 10.63 ITGA2 ITGB3 PTGS1 TBXA2R
22 10.5 PTGS1 PTGS2

GO Terms for Aspirin Resistance

Cellular components related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 8.96 PTGS1 PTGS2
2 integrin complex GO:0008305 8.62 ITGA2 ITGB3

Biological processes related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.74 APOB PTGS1 PTGS2
2 inflammatory response GO:0006954 9.67 PTGS1 PTGS2 TBXA2R
3 response to drug GO:0042493 9.65 ITGA2 PTGS2 TBXA2R
4 wound healing GO:0042060 9.61 ITGA2 ITGB3
5 cell-matrix adhesion GO:0007160 9.6 ITGA2 ITGB3
6 integrin-mediated signaling pathway GO:0007229 9.59 ITGA2 ITGB3
7 response to organic substance GO:0010033 9.58 APOB PTGS2
8 viral entry into host cell GO:0046718 9.58 ITGA2 ITGB3
9 cellular oxidant detoxification GO:0098869 9.56 PTGS1 PTGS2
10 cellular response to mechanical stimulus GO:0071260 9.55 ITGA2 PTGS2
11 fatty acid biosynthetic process GO:0006633 9.54 PTGS1 PTGS2
12 regulation of blood pressure GO:0008217 9.52 PTGS1 PTGS2
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.51 ITGA2 PTGS2
14 positive regulation of vasoconstriction GO:0045907 9.46 PTGS2 TBXA2R
15 cell adhesion mediated by integrin GO:0033627 9.43 ITGA2 ITGB3
16 response to lipopolysaccharide GO:0032496 9.43 APOB PTGS2 TBXA2R
17 prostaglandin metabolic process GO:0006693 9.4 PTGS1 PTGS2
18 cell-substrate adhesion GO:0031589 9.37 ITGA2 ITGB3
19 prostaglandin biosynthetic process GO:0001516 9.32 PTGS1 PTGS2
20 mesodermal cell differentiation GO:0048333 9.16 ITGA2 ITGB3
21 cyclooxygenase pathway GO:0019371 8.96 PTGS1 PTGS2
22 positive regulation of smooth muscle contraction GO:0045987 8.8 ITGA2 PTGS2 TBXA2R

Molecular functions related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dioxygenase activity GO:0051213 9.26 PTGS1 PTGS2
2 virus receptor activity GO:0001618 9.16 ITGA2 ITGB3
3 peroxidase activity GO:0004601 8.96 PTGS1 PTGS2
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Aspirin Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....